NEW YORK, Jan 9 – GPC Biotech has signed on to a proteomics and genomics deal with Boehringer Ingelheim pharmaceuticals, in which GPC will identify targets and pathways associated with human papillomavirus, GPC announced Tuesday.

In this project, GPC Biotech is using OliCode molecular cloning technology, PathCode yeast two-hybrid protein-protein interaction identification technology, and its bioinformatics applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.